Advanced

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

Geisler, Christian H.; Kolstad, Arne; Laurell, Anna; Raty, Riikka; Jerkeman, Mats LU ; Eriksson, Mikael LU ; Nordstrom, Marie; Kimby, Eva; Boesen, Anne Marie and Nilsson-Ehle, Herman, et al. (2010) In Blood 115(8). p.1530-1533
Abstract
Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCL better than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P < .001) than the International Prognostic Index (P > .004). Both the MIPI and the s-MIPI mainly identified 2 risk... (More)
Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCL better than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P < .001) than the International Prognostic Index (P > .004). Both the MIPI and the s-MIPI mainly identified 2 risk groups, low and intermediate versus high risk, with the more easily applied s-MIPI being just as powerful as the MIPI. The MIPIB (biological), incorporating Ki-67 expression, identified almost half of the patients as high risk. We suggest that also a simplified MIPIB is feasible. This trial was registered at www.isrctn.org as #ISRCTN 87866680. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Blood
volume
115
issue
8
pages
1530 - 1533
publisher
American Society of Hematology
external identifiers
  • wos:000274974200010
  • scopus:77949890943
ISSN
1528-0020
DOI
10.1182/blood-2009-08-236570
language
English
LU publication?
yes
id
ae56377f-6cae-4c0f-966d-5e94b2bd8cb1 (old id 1568349)
date added to LUP
2010-03-23 13:36:13
date last changed
2018-07-08 03:12:19
@article{ae56377f-6cae-4c0f-966d-5e94b2bd8cb1,
  abstract     = {Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCL better than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P &lt; .001) than the International Prognostic Index (P &gt; .004). Both the MIPI and the s-MIPI mainly identified 2 risk groups, low and intermediate versus high risk, with the more easily applied s-MIPI being just as powerful as the MIPI. The MIPIB (biological), incorporating Ki-67 expression, identified almost half of the patients as high risk. We suggest that also a simplified MIPIB is feasible. This trial was registered at www.isrctn.org as #ISRCTN 87866680.},
  author       = {Geisler, Christian H. and Kolstad, Arne and Laurell, Anna and Raty, Riikka and Jerkeman, Mats and Eriksson, Mikael and Nordstrom, Marie and Kimby, Eva and Boesen, Anne Marie and Nilsson-Ehle, Herman and Kuittinen, Outi and Lauritzsen, Grete F. and Ralfkiaer, Elisabeth and Ehinger, Mats and Sundstrom, Christer and Delabie, Jan and Karjalainen-Lindsberg, Marja-Liisa and Brown, Peter and Elonen, Erkki},
  issn         = {1528-0020},
  language     = {eng},
  number       = {8},
  pages        = {1530--1533},
  publisher    = {American Society of Hematology},
  series       = {Blood},
  title        = {The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)},
  url          = {http://dx.doi.org/10.1182/blood-2009-08-236570},
  volume       = {115},
  year         = {2010},
}